Sign In
Buy CRSP
$56.95
+4.87 (+9.35%)
At Close: Jun 04, 2026
Crispr Therapeutics: The Chance To Load Up Is Finally Here (Technical Analysis)
08:30am, Friday, 08'th Sep 2023
I warned investors in June 2022 to be wary about adding Crispr Therapeutics stock. My Sell rating has panned out accordingly as CRSP significantly underperformed the S&P 500. Despite that, CRSP bottom
CRSP Stock Alert: What to Know as CRISPR Therapeutics Co-Founder Steps Down
01:52pm, Thursday, 07'th Sep 2023
Shares of CRISPR Therapeutics (NASDAQ: CRSP ) — which specializes in gene-editing innovations — are tumbling on Thursday. The red ink follows an announcement that co-founder, President and Chairma
CRISPR Therapeutics AG (CRSP) Presents at Citi's 18th Annual BioPharma Conference Transcript
03:19pm, Wednesday, 06'th Sep 2023
CRISPR Therapeutics AG (NASDAQ:CRSP ) Citi's 18th Annual BioPharma Conference Call September 6, 2023 11:20 AM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Yigal Nochomovitz
3 Beaten-Down Biotech Stocks Bound for a Bounce Back
07:38am, Saturday, 02'nd Sep 2023
Biotech stocks soared high during the COVID-19 pandemic, as they were our only hope for new drugs and vaccines to fight the virus. However, the biotech sector received little thanks from the market wh
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
09:37am, Wednesday, 30'th Aug 2023
Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.
3 Surprisingly Underrated Stocks to Buy Right Now
06:55am, Saturday, 26'th Aug 2023
Investors aren't giving AbbVie nearly enough credit for its post-Humira strategy. CRISPR Therapeutics' pipeline offers stronger prospects than its stock performance indicates.
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
10:00am, Tuesday, 22'nd Aug 2023
CRISPR Therapeutics is using a novel technique to develop innovative therapies. Sarepta Therapeutics is developing medicines targeting a difficult-to-treat disease.
Stocks to Watch This Week's Top 7 Wall Street Upgrades
08:22pm, Monday, 21'st Aug 2023
While it's always nice to read a range of opinions about the market, targeting top Wall Street upgrades this week may be a more sensible choice. Fundamentally, the major indices have printed red ink a
3 Green Flags for Biotech Stocks in 2023 and Beyond
09:45am, Saturday, 19'th Aug 2023
Biotech will benefit immensely from new artificial intelligence tools. Companies are also starting to create some enormously complex new therapies.
The 3 Most Undervalued Cathie Wood Stocks to Buy Now: August 2023
09:32am, Wednesday, 16'th Aug 2023
Cathie Wood had a rough few years. Her flagship fund, the ARK Innovation ETF (NYSEARCA: ARKK ), hit an all-time high of $156 in 2021 before crashing back to Earth.
Missed Out on CRISPR Therapeutics? My Best Biotech Stock to Buy and Hold
06:15am, Monday, 14'th Aug 2023
It has no approved products in the market yet. But its near-term outlook is quite favorable.
3 Reasons to Buy CRISPR Therapeutics Stock, and 1 Reason to Sell
07:30am, Saturday, 12'th Aug 2023
CRISPR Therapeutics is developing a highly advanced cell-therapy platform. The stock is exposed to two major catalysts in the next few quarters.
Ready to Buy the Dip? CRISPR Therapeutics Stock Is a Smart Buy
09:45am, Friday, 11'th Aug 2023
CRISPR Therapeutics stock took a beating in the bear market. It now has two attempts to commercialize its exa-cel therapy.
The 3 Best Biotech Stocks to Buy in August
04:00pm, Wednesday, 09'th Aug 2023
Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus' spread. But medical innovations and technological breakthroughs are rapidly transforming the health
2 Great Stocks Under $100 to Buy and Hold for 10 Years
09:30am, Wednesday, 09'th Aug 2023
CRISPR Therapeutics is using an award-winning technology to develop breakthrough therapies. Block's ecosystems, which target both individuals and businesses, have seen growing success.
